John Hopkins researchers discuss Titan’s Probuphine
Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant of buprenorphine was featured in an article about new developments in managing opioid addiction that was published in the peer-reviewed journal, Drug, Design, Development and Therapy.
John Hopkins School of Medicine researchers, Marialisa Itzoe and Michael Guarnier, discuss the benefits of the Probuphine implant, which was approved by the FDA in 2016.
“Whereas sublingual forms of buprenorphine can deliver varying doses, the Probuphine implant has been created to stabilize the drug levels in the blood,” the authors write. “The implant also helps protect against purposeful drug abuse or overdosing that might occur when patients are on a daily oral regimen and take more than the allotted dosage.”
The author’s also point out that the opioid epidemic is being tackled on a variety of fronts, with “Probuphine as an expectant pharmaceutical forerunner.”
The article can be viewed here.